For many years, medicine has tried to catch up with new diseases. When a new virus appears, scientists work quickly to create a defense. Now, researchers at the University of Cambridge have found a new way. They have created the first vaccine designed entirely by artificial intelligence (AI), and it has successfully passed its first safety tests on humans.
The new vaccine targets the sarbecovirus family, which includes viruses that caused the SARS outbreak in the early 2000s and the COVID-19 pandemic in 2020. The main goal is not only to fight known diseases but also to prepare for future viruses that have not yet infected humans.
To do this, scientists used machine learning. Computer programs analyzed a large amount of genetic information from global health monitoring systems. The AI identified common features in the virus family, even in viruses found only in bats. Based on this data, the AI designed a "super-antigen," which helps the human immune system learn to recognize and fight these common viral characteristics.
Professor Jonathan Heeney from Cambridge explained that traditional vaccines often have limited protection because they are developed based on viruses already infecting people. He stated, "We've overcome the problem of traditional vaccines, which have limited protection." This new method allows us to avoid constantly updating vaccines to match new virus versions.
The vaccine recently finished a Phase 1 clinical trial with 39 healthy volunteers in Southampton and Cambridge. The results were published in June 2026. The trial showed the computer-designed vaccine is safe, with no major side effects reported. Participants also showed immune responses against known human coronaviruses and related bat viruses. However, the immune reaction in humans was less strong than in earlier animal tests.
A larger Phase 2 study is now happening to check how effective the vaccine is. If successful, this technology could be used in many standard vaccines, reducing the need for constant redesigns as viruses change. This approach, developed by DIOSvax with funding from Innovate UK, could significantly improve pandemic preparedness and potentially save millions of lives.